

B1
Cat soluble antigen, wherein the cryptic epitope is exposed and the patient generates antibodies that bind to the cryptic epitope.

At page 36, Please insert the following sentences immediately before the examples:

B2 -- The mouse hybridoma AR20.5R8233, which produces monoclonal antibody AR 20.5, was deposited with ATTC, 10801 University Blvd., Manassas, VA 20110-2209, on 23 November 1999. The mouse hybridoma B43.13: MCB-ALT1-96, which produces monoclonal antibody B43.13, was deposited with ATTC, 10801 University Blvd., Manassas, VA 20110-2209, on 18 May 2000. --

At page 28, line 17, please delete the word "and" (first word).

B3 At page 28, line 17, immediately after the word "amyloidosis" please insert the words -- drugs of abuse, multiple sclerosis, allergy, autoimmune diseases, and asthma --.

In the claims:

Please cancel claims 31 and 70.

Please amend claim 30 to read as follows.

30. (Amended) A method of stimulating the production of antibodies that bind to an epitope on a soluble antigen comprising:

B4
C administering to a host a foreign binding agent that binds to the soluble antigen;

forming a complex between the foreign binding agent, wherein the formation of the complex exposes an epitope that is unexposed when the foreign binding agent is not complexed to the antigen;

and allowing the host to generate antibodies that bind to the exposed epitope.

Please amend claim 61 to read as follows.

- B5 61. (Amended) A composition for altering immunogenicity comprising a modified antigen bound to a foreign binding agent.

{ Please amend claim 66 to read as follows. }

66. (Amended) A method of altering immunogenicity in a patient comprising administering to the patient a composition comprising a binding agent that induces the production of AB3 and AB3'; and

permitting the binding agent to specifically bind to a soluble antigen in the patient, wherein the patient obtains a beneficial effect.

B6 { Please amend claim 67 to read as follows. }

67. (Amended) A method of using a binding agent to induce AB3 and AB3' in a patient comprising administering to the patient a composition comprising a binding agent and allowing the binding agent to induce the production of AB3 and AB3', wherein the patient obtains a beneficial effect.

{ Please amend claim 69 to read as follows. }

69. (Amended) A method of stimulating the production of antibodies which bind to a soluble antigen in a patient comprising:

B7 administering to the patient a non-radiolabeled monoclonal antibody that specifically binds to the soluble antigen in an amount sufficient to stimulate the production of anti-anti-idiotypic antibodies that immunoreact with an antigen-antibody complex formed between the monoclonal antibody and the antigen, wherein the production of anti-anti-idiotypic antibodies provides a beneficial effect to the patient.

{ Please amend claim 87 to read as follows. }